Frank Borriello, MD, PhD, on Next Steps for SUPLEXA-101 for Solid Tumors
The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed progress of the phase 1 trial and possible future evaluations of the therapy.
Frank Borriello, MD, PhD, on Promising Activity of SUPLEXA-101 Across Cancers
The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.